Creative Planning
MDGL icon

Creative Planning’s Madrigal Pharmaceuticals MDGL Stock Holding History

Creative Planning’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-400
Closed -$3.56K – 3132
2024
Q1 		$3.56K Buy
+400
New +$94.2K ﹤0.01% 2895

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Creative Planning's MDGL Position: Q1 2026 in Review

Creative Planning increased its Madrigal Pharmaceuticals (MDGL) stake by 7.8% in Q1 2026, buying an estimated $413K and bringing the position to 12,005 shares worth $6.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1018.

Creative Planning first reported a position in MDGL in Q3 2013 and has held it in 27 quarters since. The position peaked at $6.49M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Creative Planning held 12,005 shares of Madrigal Pharmaceuticals worth $6.28M as of Q1 2026.
  • Creative Planning bought 864 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $413K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1018 holding.
  • Creative Planning first reported a position in Madrigal Pharmaceuticals in Q3 2013 and has held it in 27 quarters since.
  • Creative Planning's Madrigal Pharmaceuticals position peaked at $6.49M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.